Factors associated with IL-6 levels during HIV infection Álvaro Borges, Jemma O’Connor, Andrew Phillips, Frederikke Rönsholt, Sarah Pett, Michael Vjecha,

Slides:

Advertisements

Similar presentations

Jayaweera DT, Campa A, Casillas VJ, Martinez SS, Shin DH, Li Y, Young S, Baum MK.

Advertisements

WHITE BLOOD CELL COUNT SECULAR TREND AND MORTALITY: THE BALTIMORE LONGITUDINAL STUDY OF AGING C.Ruggiero; E.J.Metter; A.Cherubini; M.Maggio; R.Sen; S.S.Najjar;

Background  Hypertrigliceridaemia is common in patients with HIV, especially those taking protease inhibitors (PIs) or with lipodystrophy.  Although,

Prevalence of and Progression to Abnormal Non-Invasive Markers of Liver Disease (APRI and FIB-4) among US HIV-infected Youth Kapogiannis B, Leister E,

Chronic diseases in HIV Francois Venter Wits Reproductive Health & HIV Institute

Why is inflammation elevated in treated HIV infection and why does it matter? Steven G. Deeks Professor of Medicine University of California, San Francisco.

Cardiovascular Complications of HIV Mark Boyd MD, FRACP The Kirby Institute for infection and immunity in society 7 th IAS Conference Kuala Lumpur, Malaysia.

HIV Disease in Older Patients Donna M. Gallagher, ANP The International AIDS Society–USA DM Gallagher, ANP. Presented at IAS–USA/RWCA Clinical Conference,

Protective HLA Class I alleles are associated with reduced immune activation in Primary HIV infection Elizabeth Hamlyn 1, Stephen Hickling 2, Abdel Babiker.

Ambulatory Blood Pressure Profiles in Adolescents with Type 1 Diabetes Andrew J. Ellis 1,2, B.A.; David M. Maahs 2, M.D. Ph.D.; Franziska K. Bishop 2,

HDL Particles but not LDL Particles Predict Cardiovascular Disease Events in HIV Patients: Results from Strategies for Management of ART Study (SMART)

Cell- and Tissue-based Measures of Viral Persistence Are Associated with Immune Activation and PD-1-Expressing CD4+ T cells H Hatano 1, V Jain 1, PW Hunt.

Hemoglobin A 1c in Hemodialysis Patients Source: Ix JH. Hemoglobin A1c in hemodialysis patients: Should one size fit all? Clin J Am Soc Nephrol. 2010;5:1539–1541.

Risk of serious disease and death in people with HIV viral suppression on ART: an epidemiologic perspective The Lancet and Cell Meeting What Will it Take.

Results Table 1: Factors associated with advanced liver fibrosis in univariable analysis among 216 chronic HCV patients Background There is a clinical.

Global impact of ischemic heart disease World Heart Federation, 2011.

AfterBefore PTH pg/ml PTH pg/ml AfterBefore Case Report 1) Age 53, 17 yrs HIV infection TDF/FTC/EFZ Baseline 25(OH)D.

The Effect of Syphilis Co-infection on Clinical Outcomes in HIV-Infected Persons The Effect of Syphilis Co-infection on Clinical Outcomes in HIV-Infected.

Factors associated with Mortality in the Study of Fat Redistribution and Metabolic Change in HIV infection Leslie Modrich 1, Rebecca Scherzer 1,2, Andrew.

Fatal and Non-fatal Hepatic Failure in HIV-infected versus HIV-uninfected Persons Enrolled in Kaiser Permanente California (KP), a Large Managed Care Organization.

Purpose and Hypothesis Results Implications Discussion Acknowledgment Background State/Trait Depression and Hostility as Predictors of Interleukin-6 Levels.

Occult hepatitis B virus (HBV) and hepatitis C virus (HCV) viremia in women with and at-risk for HIV/AIDS Taylor L, Gholam P, Delong A, Rompalo A, Klein.

HIV and serious non-AIDS conditions Five Years after the SMART Study, a Paradigm Shifting Trial INSIGHT Symposium XIX International AIDS Conference Washington.

Comparison of INSTI vs PI  FLAMINGO  GS  ACTG A5257  WAVES.

Coagulation / Fibrinolytic Factors in PCOS. The Alternative Hypothesis : Conversely, PCOS women may be protected from later life onset of CHD by the altered.

The Interplay of the Osteoprotegerin/RANKL Axis and Dysfunctional HDL in HIV-Infected Adults AIDS Clinical Trials Group Study NWCS 332/A5078 Kelesidis.

#735 KA Lichtenstein 1, C Armon 2, K Buchacz 3, AC Moorman 3, KC Wood 2, JT Brooks 3, and the HOPS Investigators 1 University of Colorado Health Sciences.

T-Cell Senescence & Inflammation HIV Research Catalyst Forum, April

Neurocognitive Impairment in HIV-Infected Subjects on HAART: Prevalence and Associations Kevin Robertson *1, Kunling Wu 2, Thomas Parsons 1, Ron Ellis.

Introductory talk D Costagliola.

Effect of Hypertension and Dyslipidemia on glycemic control among Type 2 Diabetes patients in Thailand Dr. Mya Thandar DrPH Batch 5 1.

Metabolic Syndrome in HIV- Infected Patients from MTCT-Plus, Thai Outpatient Population J. JANTARAPAKDE1,2,*, C. CHATURAWIT1,2, S. PENGNONYANG1,2, W. PIMA1,

The role of treatment versus disease in causing premature non-AIDS morbidity Judith S. Currier, MD University of California, Los Angeles.

Evidence for the link between markers of inflammation, coagulation and immune activation and end organ disease Session: Immune Activation/Inflammation.

Chapter 1: CKD in the General Population 2015 A NNUAL D ATA R EPORT V OLUME 1: C HRONIC K IDNEY D ISEASE.

Outcomes of Antiretroviral Treatment Programs in Rural Lesotho: Health Centers and Hospitals Compared Niklaus Labhardt, Motlalepula Sello, Mamokone A.

ALLHAT 6/5/ CARDIOVASCULAR DISEASE OUTCOMES IN HYPERTENSIVE PATIENTS STRATIFIED BY BASELINE GLOMERULAR FILTRATION RATE (3 GROUPS by GFR)

HIV infection and cardiovascular diseases Matthew S. Freiberg, MD, MSc University of Pittsburgh School of Medicine and Graduate School of Public Health.

Lifestyle diseases in People living with HIV

Probability and odds Suppose we a frequency distribution for the variable “TB status” The probability of an individual having TB is frequencyRelative.

Strategies for Management of Antiretroviral Therapy Study Wafaa El-Sadr and James Neaton for the SMART Study Team.

The Impact of Darunavir/ritonavir (DRV/r) & Raltegravir (RAL) in the Clinic: A New Era for Treatment-Experienced Patients? M. Mugavero 1, H. Lin 1, J.

6/5/ CARDIOVASCULAR DISEASE OUTCOMES IN HYPERTENSIVE PATIENTS STRATIFIED BY BASELINE GLOMERULAR FILTRATION RATE (4 GROUPS by GFR) ALLHAT.

Conclusions Materials and Methods Background Objectives HIV-1 RNA is the most significant determinant of cervical HIV-1 shedding. Shedding has also been.

For the primary endpoint, the mean eGFR (2012 CKD- EPI Cr-CC) change at 96 weeks was significantly greater for ABC/3TC vs. TDF/FTC (Figure 1). In the

Slideset on: Patel P, Hanson DL, Sullivan PS, et al. Incidence of types of cancer among HIV-infected persons compared with the general population in the.

Acute Renal Failure in HIV- Infected Individuals Greatly Increases Risk for In-Hospital Mortality Slideset on: Wyatt CM, Arons RR, Klotman PE, Klotman.

Date of download: 6/3/2016 From: Report of the NIH Panel To Define Principles of Therapy of HIV Infection* Ann Intern Med. 1998;128(12_Part_2):

Am J Kidney Dis. 2014;63(6): R3 박세정 /prof. 이태원 Comparative Effectiveness of Early Versus Conventional Timing of Dialysis Initiation in Advanced.

Iron, Cholesterol, and Cancer Brian J. Wells, MD, MS The Cleveland Clinic Foundation.

Circulation. 2014;129: Association Between Plasma Triglycerides and High-Density Lipoprotein Cholesterol and Microvascular Kidney Disease and Retinopathy.

내과 R1 문정락 / prof. 정경환 N Engl J Med 369;10 nejm.org 932 september 5, 2013.

Slideset on: Emery S, Neuhaus JA, Phillips AN, et al. Major clinical outcomes in antiretroviral therapy (ART)-naive participants and in those not receiving.

－ Higher SBP visit-to-visit variability (SBV) has been associated

Higher HDL, better brain

Inflammation Markers and The Risk of Non-AIDS Events

Higher rate of antiretroviral therapy reinitiation among HIV-HBV coinfected patients in the episodic arm of the SMART study Dore G.1, Soriano V.2, Neuhaus.

Chronic Kidney Disease in HIV Infection: An Urban Epidemic

ACC 2018 Orlando, Florida Interleukin-1b Inhibition with Canakinumab and Cardiovascular Event Reduction Among Patients with Moderate Chronic Kidney Disease.

Switch to DTG-containing regimen

Cases from the Clinic(ians): Case-based Panel Discussion

Volume 4, Issue 3, Pages e105-e112 (March 2017)

Cholesterol Management in HIV-infected and Uninfected Patients: The Veterans Aging Cohort Study Leaf, DA, Goulet J, Goetz MB, Oursler KA, Gilbert C, Frieberg.

Switch to DTG-containing regimen

Core Competency 1: Epidemiologic Background of HIV/HCV Co-infection in the United States Lesson 2: Morbidity and Mortality in HCV Co-infected People Living.

Effect Modifiers.

Share your thoughts on this presentation with #IAS2019

ACC 2018 Orlando, Florida Interleukin-1b Inhibition with Canakinumab and Cardiovascular Event Reduction Among Patients with Moderate Chronic Kidney Disease.

Correlation of HIV-1 replication fitness, as measured by the Monogram Biosciences RC assay, with baseline CD4+ T-cell count (a) and baseline plasma HIV-1.

Volume 13, Pages (August 2019) Predictors of Ischemic and Hemorrhagic Strokes Among People Living With HIV: The D:A:D International Prospective.

Presentation transcript:

Factors associated with IL-6 levels during HIV infection Álvaro Borges, Jemma O’Connor, Andrew Phillips, Frederikke Rönsholt, Sarah Pett, Michael Vjecha, Martyn French and Jens Lundgren, for the INSIGHT SMART and ESPRIT Study Groups and the SILCAAT Scientific Committee.

Background IL-6 is a pro-inflammatory cytokine that regulates various pathophysiological processes. Elevated plasma IL-6 levels have been linked to cardiovascular disease, cancer and death. BMI, older age, smoking, CVD and DM associated with higher IL-6 among HIV-uninfected persons. Compared to the general population, treated HIV+ persons have higher IL-6, but few data on the factors associated with IL-6 levels currently exist. Kuller PloS Med 2008 Neuhaus JID 2010 Duprez PlosOne 2012 Borges AIDS 2013 Tanaka Cancer Immunol 2014

Methods Inclusion Criteria: All SMART, ESPRIT and SILCAAT participants whose plasma IL-6 levels were measured at study entry (N=9,864). Statistical analysis: Independent factors associated with IL-6 levels were identified by multivariable linear regression models Log 2 transformed IL-6 levels were used as the dependent variable. Back transformed exponentiated estimates (fold differences in IL-6 levels) with 95% CI were calculated to assess the contribution of baseline variables to the variance of IL-6 levels

Methods As some variables of interest were only available for one or two of the three studies, regression models were fitted to three different datasets: SMART, ESPRIT and SILCAAT (N=9,864): Demographics (age, gender, ethnicity, BMI) HIV-specific variables (nadir and baseline CD4 + cell counts, HIV RNA) ART use and ART regimens Markers of inflammation (hsCRP) and activated coagulation (D-dimer) SMART and ESPRIT (N=6,938): Co-morbidities (HBV, HCV, diabetes mellitus, cardiovascular disease) Renal function (eGFR) SMART participants (N=4,498): Smoking Education level Cholesterol levels (LDLc and HDLc)C

Results: Renal function, Serum lipids and IL-6 levels Higher eGFR at baseline was associated with lower IL-6 (FD [95% CI]: 0.98 [ ] per 10 mL/min/1.73m 2, p= 0.01) There was a negative correlation between serum cholesterol levels and IL-6: Higher LDLc (0.99 [ ]/10 mg/dL, p<.0001) and higher HDLc (0.98 [ ]/10 mg/dL, p= ) were both associated with lower IL-6 levels

Conclusions Higher IL-6 levels in HIV+ persons were associated with older age and non-black race, higher BMI, lower education, ongoing HIV replication, low nadir CD4 counts, comorbidities, smoking, decreased renal function and lower serum lipids PI-based ART regimens were associated with higher IL-6 levels while nevirapine use was associated with lower IL-6 levels The enhanced inflammation seen during HIV infection is probably determined by a synergistically deleterious interaction of HIV-related and -unrelated morbidity.

Acknowledgements Funding: NIH [grant numbers: U01AI46957 and U01AI (ESPRIT); U01AI and U01AI46362 (SMART)] INSIGHT SMART and ESPRIT Study Groups and the SILCAAT Scientific Committee INSIGHT Executive Committee and INSIGHT SSC